Autopsy report · NCT03289143
A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease
Cause of deathOther
“Study was terminated during Open Label Extension period because analyses of placebo-controlled Blinded portion of study did not show any evidence of clinical efficacy or modulation of accumulation of tau PET signal at any of the doses studied.”
Life of this trial
- Ran for about 3 years 3 months before it stopped.
- 457 participants enrolled.
- Results were posted on the registry 1 year 2 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Genentech, Inc.
- Sponsor type
- Industry
- Conditions
- Alzheimer's Disease
- Interventions
- Semorinemab; Placebo; [18F]GTP1
- Participants
- 457
- Sites
- 133
- Countries
- Australia, Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Poland, Spain, Sweden, United Kingdom and more
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.